Sangamo
- مرداد- 1397 -2 مرداد
Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition
Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition Sangamo Therapeutics has agreed to acquire TxCell for €۷۲ million ($84 million), the companies…
-- بیشتر بخوانید -- - آذر- 1396 -14 آذر
Sangamo Therapeutics: راه حل های مهندسی ژنوم برای بیماری های نادر
Summary Sangamo just became the first company to do in vivo genome editing in the clinic. One of the four trials Sangamo has in the…
-- بیشتر بخوانید -- - 2 آذردیگر
Sangamo Genome Editing Trial, Assessing MPS II Candidate, Treats First Patient
Sangamo Therapeutics said today it has treated the first patient in the Phase I/II CHAMPIONS clinical trial assessing its in vivo genome-editing candidate therapy SB-913…
-- بیشتر بخوانید -- - آبان- 1396 -18 آباندیگر
AP Exclusive: US scientists try 1st gene editing in the body
OAKLAND, Calif. (AP) — Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change a…
-- بیشتر بخوانید --
